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The median OS for patients who received M-MUD was 8.1
months while it was 14.2 months for patients who received
F-MRD (p¼0.72) Fig1. Median DFS for patients who received
M-MUD was 6 months while it was 7.2 months for patients
who received F-MRD (p¼0.94). The CI rates of aGVHD III-IV,
extensive chronic GVHD, REL and NRM at 12 months in M-
MUD vs F-MRD were 13% vs 16% (p¼0.69), 21% vs 27%
(p¼0.61), 38% vs 44% (p¼0.65), and 16% vs 14% (p¼0.79),
respectively. The CI of steroid refractory (SR) GVHD in M-
MUD vs F-MRD was 24% vs 32% (The Hazard Ratio of SR
GVHD in M-MUD vs F-MRD is 0.711 (95% conﬁdence interval
is 0.29-1.72, p¼0.45)) Fig 2. Other variables considered in
univariate analysis for SR GVHD were recipient age (p¼0.55),
disease status (p¼0.64), MAC vs other regimens (p¼0.58).
Conclusion: In this small cohort from a single center, we
found that compared to M-MUD, F-MRD had a trend for
higher rates of SR GVHD after peripheral blood allo-SCT in
adult male patients, although not statistically signiﬁcant.
There was no impact of F-MRD compared to M-MUD on OS,
DFS, REL, NRM or rates of acute or chronic GVHD. However,
the absence of statistical impact should be interpreted with
caution given the retrospective design of the study and
because we cannot exclude a possible limiting effect of a
small number of patients.Figure 1.
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Background: Primary Myeloﬁbrosis (PMF) and Post PV/ET
MF are a group of myeloproliferative neoplasms that are
characterized by marrow ﬁbrosis, cytopenias, constitutional
symptoms, and splenomegaly. Allogeneic stem cell trans-
plant (ASCT) remains the only potential curative modality.
The increased risk of morbidity and mortality warrants
careful selection of candidates. Age, performance status (PS)
and HCT-CI scores are all factors that may affect outcomes
related to ASCT. Use of JAK inhibitor therapy prior to HCT
may lead to reduction in splenomegaly, decrease in consti-
tutional symptoms, and improved PS. We report our expe-
rience here at Mayo Clinic Arizona using JAK inhibition prior
to ASCT.
Methods: We conducted a retrospective review of all pa-
tients from 2011 to current with PMF or post ET/PV-MF who
underwent treatment of ruxolitinib followed by ASCT. Pa-
tient demographic and transplant data were analyzed from a
comprehensive database. The use of such data for reporting
purpose was approved by the Mayo Clinic Arizona Institu-
tional Review Board.
Results
Patient characteristics
Eight patients underwent ruxolitinib therapy prior to
ASCT. Mean age was 61 yrs.
Disease characteristic
DIPSS risk was high risk in 6 and intermediate 2 in 2. The
JAK 2 v617 mutation was present in 7 patients. Four patients
had PMF and 4 had post PV-MF. None of the patients un-
derwent splenectomy. The median duration of ruxolitinib
was 7.8 months. Improvement in PS was seen 4 pts, stable PS
was seen 3 patients and data regarding PS was missing in 1.
Six of the 8 patients had reduction in their spleen size prior
to ASCT. The median daily dose of ruxolitinib was 25.6 mg/
day.
Transplant characteristics
One patient underwentmyeloablative conditioning (MAC),
5 reduce toxicity, and2RIC. All 8 patients hadunrelateddonors
with1patienthavingamismatchunrelateddonor.Graftversus
host disease prophylaxis was tacrolimus/methotrexate in 6
patients and tacrolimus/MMF in 2 patients. All 8 patients
received in vivo T cell depletion with rabbit ATG and had
peripheral stem cells as their graft source. Of the 8 patients, 1
hadprimarygraft failure2had relapseddiseasebeforeday100.
All 3 of these patients were conditioned with Bu/Flu RIC
regimen. None of the patients experienced tumor lysis
syndrome or cardiogenic shock.
Conclusion: In our small cohort of patients that received
ruxolitinib pre ASCT improvement in performance status and
spleen size were seen. Our data is still immature to make any
meaningful comments of outcomes, but all patients tolerated
the ruxolitinib and no major adverse outcomes were seen
related to the ruxolitinib such as cardiogenic shock or tumor
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S283lysis syndrome as seen in a recent French study. Further
studies are needed to formally evaluate the impact on JAK
inhibitors on transplant both pre and post setting.403
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Introduction: Chronic Graft-versus-Host Disease (cGvHD)
occurs in 40%-70% of allogeneic hematopoietic stem cell
transplantation. Their quality of life is severely affected, and
the two-year overall survival is about 60%. cGvHD displays
autoimmune-like and ﬁbrotic symptoms. B cell activation
appears to be involved in this process, however, little isFigure.known about the role of the macrophage in cGvHD. Previ-
ously, we reported a humanized cGvHD model with lung
ﬁbrosis induced by G-CSF mobilized human PBMCs
(G-hPBMCs) 8 weeks post transplantation. We further
developed the model with liver ﬁbrosis.
Materials and Methods: NSGmice were treated with 20mg/
kg cyclophosphamide (CTX) at day -3 and -2 combined with
200cGy total body irradiation (TBI) at day -1. This was fol-
lowed by injection of 1x106 G-hPBMCs or 1x105 CD34+ cells
at day 0. Engraftment was assessed in PB and in speciﬁc
target organs by either ﬂow cytometry or immunohisto-
chemistry (IHC). Liver samples were taken 8 weeks post
transplantation, and ﬁxed and stained with hematoxylin and
eosin and Masson’s trichrome. The specimens were evalu-
ated by a pathologist who was blinded to the treatment
group. Serumwas collected 8weeks post transplantation and
analysed for human cytokine/chemokine array.
Results: The percentage of hCD45+ cells in PB showed a
signiﬁcant increase at 8 weeks compared to 4 weeks
(p¼0.01). Mice that received 1x106 G-hPBMCs had hCD45+
cells in PB at a median of 18.0% (1.6-79.4%), and comprised
more than 95% of hCD3+ Tcells. Histology showed peri-portal
and bile duct inﬂammation and ﬁbrosis, with aggregation of
hCD68+ macrophages with lymphocytes (Figure 1). There
was a correlation between liver pathology score and
